Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE Additionally, the use of PSMA tracers in systemic radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC), as well as non-prostatic specific uptake of PSMA tracers and the use of PSMA imaging to manage therapy have been described. 28217987 2017
Metastatic castration-resistant prostate cancer
0.100 GeneticVariation disease BEFREE The aim of this study was to measure overall-survival (OS) in mCRPC patients who received either abiraterone or enzalutamide prior to PSMA therapy. 29262549 2017
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE Recent successes in the treatment of metastatic castration-resistant prostate cancer (mCRPCa) by systemic endoradiotherapy has sparked renewed interest in developing small molecule ligands targeting prostate-specific membrane antigen (PSMA) and chelators capable of stable complexation of metal radionuclides for imaging and therapy. 29055836 2017
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE We aimed to evaluate dosimetry, safety and efficacy of 177Lu-PSMA-617 radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC).Fifteen patients each received two cycles of 3.7 GBq (n = 5) or 6.0 GBq (n = 10) 177Lu-PSMA-617 at an eight to ten weeks interval. 27683041 2017
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE <sup>68</sup> Ga-PSMA PET/CT shows more lesions than bone scans, but data on diagnostic performance are very limited and indicate improved diagnostic performance in primary staging but not in mCRPC. 29082604 2017
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE Thirty-four men with metastatic castration-resistant prostate cancer received PSMA-RLT with <sup>131</sup>I-MIP-1095. 28280855 2017
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy is increasingly used in metastatic castration-resistant prostate cancer. 27660138 2017
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE Lu-DKFZ-PSMA-617 therapy is a safe option in the treatment of mCRPC patients. 27782913 2017
Metastatic castration-resistant prostate cancer
0.100 AlteredExpression disease BEFREE A targeted theragnostic approach based on increased expression of prostate-specific membrane antigen (PSMA) on PC cells is an attractive treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). 28083690 2017
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT. 27922871 2017
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE <sup>177</sup>Lu-DKFZ-PSMA-617 radionuclide therapy is a safe and effective approach in the treatment of mCRPC patients. 27506431 2017
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. 29026946 2018
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer. 30036254 2018
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE We aimed to investigate the safety, efficacy, and effect on quality of life of [<sup>177</sup>Lu]-PSMA-617 in men with metastatic castration-resistant prostate cancer who progressed after standard treatments. 29752180 2018
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE We performed a meta-analysis on the therapeutic effects of prostate-specific membrane antigen (PSMA)-617 labeled with lutetium-177 (Lu-PSMA-617) in patients with metastatic castration-resistant prostate cancer (mCRPC). 30059428 2018
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE There is increasing evidence of encouraging response rates and a low toxicity profile of radioligand therapy (RLT) of metastatic castration-resistant prostate cancer using <sup>177</sup>Lu-labeled PSMA ligands. 29873291 2018
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE To determine the safety and efficacy of BIND-014, a PSMA-directed docetaxel-containing nanoparticle, in patients with metastatic castration-resistant prostate cancer (mCRPC). 29978216 2018
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE This report describes a case of a 54-year-old man who underwent lutetium-177-PSMA therapy in the setting of metastatic castration-resistant prostate cancer (mCRPC) in the University Medical Center Utrecht. 30301726 2018
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE The aim of this work was to simulate the effect of prostate-specific membrane antigen (PSMA)-positive total tumor volume (TTV) on the biologically effective doses (BEDs) to tumors and organs at risk in patients with metastatic castration-resistant prostate cancer who are undergoing <sup>177</sup>Lu-PSMA radioligand therapy. 29419479 2018
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE Prostate-specific membrane antigen (PSMA)-targeted therapy with <sup>177</sup>Lu-PSMA-617 is a therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC). 29651569 2018
Metastatic castration-resistant prostate cancer
0.100 AlteredExpression disease BEFREE The prevalence of increased surface expression and constitutive internalization of PSMA make it an attractive target for an antibody-drug conjugate (ADC) approach to treating patients with mCRPC. 30065100 2018
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE There is a controversy as to the relative efficacy of <sup>177</sup>Lu prostate specific membrane antigen (PSMA) radioligand therapy (RLT) and third-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). 29247284 2018
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE PATIENT SUMMARY: We analyzed the treatment outcome and toxicity of prostate-specific membrane antigen-targeted radioligand therapy in patients with metastatic castration-resistant prostate cancer. 30473431 2019
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE Prostate-specific membrane antigen (PSMA) is an attractive target for radionuclide therapy of metastatic castration-resistant prostate cancer (mCRPC). 31831560 2019
Metastatic castration-resistant prostate cancer
0.100 Biomarker disease BEFREE Recent years have seen the start of treatment of metastatic castration-resistant prostate cancer with prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT), especially <sup>177</sup>Lu-PSMA-617. 30850503 2019